Displaying 11 - 20 of 89 for Cancer - All
  • Biospecimen Banking (H-37203)
    • This study obtains samples from HIV-positive and negative patients with HPV-related cancers of the oropharynx, cervix and anus.
  • BLAST Study (H-36486)
    • The purpose of this study is to compare patient tumor tissue before and after treatment with standard chemotherapy (gemcitabine+cisplatin) plus celecoxib.
  • Blood Cell Disorders Study (H-35101)
    • This study will evaluate pediatric patients with malignant or non-malignant blood cell disorders who are having a blood stem cell transplant depleted of T cell receptor (TCR) alfa and beta cells that comes from a partially matched family donor.
  • Cabozantinib-S-Malate Study (H-33163)
    • This phase I trial studies the side effects and best dose of cabozantinib-s-malate in treating patients with advanced solid tumors and human immunodeficiency virus.
  • CADENCE Study (H-36960)
    • The purpose of this study is to determine whether the combination of docetaxel and carboplatin is an effective treatment for patients with triple negative breast cancer.
  • CareSTEPS Study (H-38998)
    • The purpose of this study to evaluate a program developed for the family caregivers of advanced lung cancer patients.
  • CARPASCIO Study (H-33133)
    • The purpose of this study is to see whether this therapy might help people with lymphoma or leukemia after a stem cell transplantation from a donor.
  • CHARKALL Study (H-23574)
    • Patients have a type of cancer called NHL, Multiple Myeloma (MM) or CLL. The lymphoma, MM or CLL has come back or has not gone away after treatment. This is a gene transfer research study using special immune cells.
  • CHARMS Study (H-33903)
    • Investigators want to see if they can use banked multivirus-specific T cells to treat infections of these viruses after a transplant: Epstein Barr virus (EBV), cytomegalovirus (CMV), BK virus, JC virus, adenovirus or HHV6 (Human Herpes Virus 6).
  • Chemotherapy and Pelvic Radiation Therapy Study (H-37218)
    • Study of chemotherapy and pelvic radiation therapy to see how well they work when given with or without additional chemotherapy in treating patients with high-risk early-stage cervical cancer after radical hysterectomy.